In elderly treated hypertensive patients, high MS of systolic BP predicts coronary events in dippers but not in nondippers. Nondippers, however, show higher risk of coronary events independently of MS in systolic BP.

Increased BP variability is associated with higher incidence of cardiovascular events, but also with other relevant prognostic factors. Indeed, in multivariate analysis the possible adverse prognostic impact of BP variability is no longer evident. Thus, in treated hypertension, BP variability evaluated by noninvasive monitoring is not an independent predictor of outcome.

Hypertensive patients at low-medium risk with MetS are at higher cardiovascular risk than those without MetS. Metabolic syndrome may be a useful tool for clinicians to identify subjects who are at increased risk when traditional assessment may indicate low-medium risk.

Highlights Hyperinflammation in COVID-19 activates blood coagulation increasing thrombotic risk. Tocilizumab blocks IL-6 receptor and may improve inflammatory-induced hypercoagulability. Tocilizumab was associated with rapid and sustained coagulation improvement. These benefits were consistent independently of thromboprophylaxis dose.

Highlights Early treatment with low-dose tocilizumab TCZ (324 mg, administered subcutaneously in two simultaneous 162 mg injections) was used to prevent progression of disease in a subgroup of patients with moderate COVID-19 pneumonia and hyperinflammation. Low-dose subcutaneous tocilizumab TCZ (324 mg) was well-tolerated with no significant adverse effects. Low-dose subcutaneous tocilizumab TCZ (324 mg) was associated with a rapid and significant reduction in C reactive protein (CRP) paralleled by a progressive improvement in oxygenation as reflected by the ratio of partial pressure of oxygen to fraction of inspired oxygen (P/F) ratio. None of the TCZ-treated patients had disease progression, suggesting that IL-6 receptor blockade with subcutaneous TCZ may prevent COVID-19 progression when administered early in the course of disease.